Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial

Michał Szczypior, Wojciech Połom, Piotr Wąż, Marcin Matuszewski

1Department of Urology, Medical University of Gdansk, Gdansk, Poland
2Department of Nuclear Medicine, Medical University of Gdansk, Gdansk, Poland

Abstract

Introduction: Refractory idiopathic overactive bladder (RIOAB) is a common condition with a significant negative impact on quality of life. Intravesical injection of botulinum toxin A (BTX-A) is widely used as an intervention for these cases. In the standard method the drug solution is colorless. The addition of dye such as methylene blue (MB) facilitates visualization during the procedure and may have a beneficial effect.

Aim: To evaluate the injection of BTX-A with the addition of methylene blue (MB) against a standard method in the treatment of RIOAB.

Material and methods: In this 1-center, single-blinded, randomized controlled trial, we recruited 80 patients with RIOAB. A total of 39 were assigned to injection into the bladder wall of 100 U BTX-A with MB (in 9.5 ml normal saline + 0.5 ml MB), and 41 were assigned to BTX-A 100 U alone (in 10 ml normal saline). Cystoscopy with a submucosal injection of the solution was performed systematically, including the bladder triangle. Participants were assessed 6 and 12 weeks after the treatment using a Likert scale and OABSS questionnaire.

Results: Significant improvement was similar (result of 1 or 2 on the Likert scale) and was achieved in 66.7% and 69.2% after 6 weeks and in 63.9% and 64.1% after 12 weeks in the BTX-A + MB group and only-BTX-A group, respectively. There was a significant difference between the two groups (p = 0.049) in the total number of patients with complications: 2 (5.6%) vs. 9 (23.1%).

Conclusions: The addition of MB to BTX for treatment of RIOAB patients does not influence treatment efficacy, while it limits the risk of complications.

Key words: urinary incontinence, methylene blue, overactive bladder, botulinum toxin A.

Introduction

Injections of botulinum toxin A (BTX-A) administered to the bladder wall have been a well-established method in the treatment of refractory idiopathic overactive bladder (RIOAB) for many years now. According to the definition proposed by Phee et al. [1], RIOAB is recognized in the absence of the effects of pharmacological treatment or its discontinuation due to adverse effects. In order to achieve the therapeutic effect of BTX-A in RIOAB therapy, it is important to properly deposit the drug within the bladder wall. There are two options described in the
literature; the first one consists of injections into the detrusor muscle, which remains the standard treatment technique approved by the US Food and Drug Administration [2, 3]. The second method consists of submucosal injections, which reportedly are equally effective and may allow for more precise distribution of the drug [4]. Nevertheless, both methods require great meticulousness: if the insertion is too shallow, it may cause extravasation of the drug into the bladder cavity, whereas if it is too deep, the administration of the drug may go outside the bladder, sometimes intraperitoneally. Although there are no data on the possible side-effects of such a situation, it obviously means a partial loss of the dose of the drug, which may affect the final therapeutic effect.

Routinely, BTX-A should be administered evenly over the entire surface of the bladder, omitting the bladder trigone, in order to avoid the risk of vesico-ureteral reflux – even though previous studies have not confirmed the occurrence of this phenomenon. However, the current guidelines continue to recommend excluding the bladder trigone [5, 6].

According to the standard protocol, the drug solution is prepared with 0.9% NaCl. The resulting mixture is colorless, which renders any observation of the spilled volume of the drug impossible. Moreover, puncture sites are often poorly visible as well, which becomes an even greater issue in case of bladder bleeding. In such situations, achieving even distribution of injections can be difficult. A potential solution to this problem may be the addition of a dye to the BTX-A solution. This study presents and discusses the results of treatment of patients with RIOAB using botulinum toxin with the addition of methylene blue (MB).

**Aim**

Evaluation of the results of RIOAB treatment with BTX-A with the addition of MB in comparison to the standard method.

**Material and methods**

This clinical trial was designed as a prospective, single-blind (patient-blind), randomized trial.

We screened, blinded, and randomly selected our subjects from a group of eighty patients with RIOAB diagnosed through a urodynamic study and 2-day bladder diary. Patients had been inadequately managed by anticholinergic or B-mimetic therapy (insufficient efficacy during at least 3 months of treatment or intolerable side effects). Enrolled patients experienced at least 3 urinary urgency episodes in a 2-day bladder diary, an average of ≥ 8 micturitions per day, and a postvoid residual (PVR) urine volume ≤ 100 ml. Patients had to be willing to initiate clean intermittent catheterization (CIC) after treatment, if necessary. The patients were divided into two groups: a BTX-A with MB group, and a non-MB control group.

The following exclusion criteria were applied: previous lower urinary tract surgery, active urinary tract infection (UTI), impaired renal function, neurologic disease, bladder disease affecting bladder function, severe coagulopathy, bladder outlet obstructions (BOOs), active hematuria, deficiency of glucose-6-phosphate dehydrogenase, diabetes, pregnancy, inability to complete the questionnaire form.

**Flow diagram**

Eventually, seventy-five randomly selected patients were analyzed in the study. The average age was 45.6 (range: 19–81). The study was conducted between February 2014 and December 2017. The severity of RIOAB, including frequency, nocturia, urgency and episodes of urinary incontinence, were assessed using the Overactive Bladder Symptom Score (OABSS). Global changes in the quality of life were assessed using the Likert scale. In each case a dose of 100 IU of botulinum toxin A (Botox) was used. For the group treated with MB the drug was dissolved in 9.5 ml of 0.9% NaCl. In each case 0.5 ml of MB 1% (10 mg/ml) was added to the solution of the drug, which resulted in its coloring. The study was approved by the local research ethics committee. All the patients provided their written informed consent before participation. The safety of using the BTX-A solution with the addition of MB has been pharmacologically tested; we have presented the results of these studies in our previous publication (Figure 1) [7].

Following our primary observations, a fixed dose of 0.5 ml of methylene blue proved to be the smallest dose which effectively improved the intraoperative observation. For the group without MB the drug was dissolved in 10 ml of 0.9% NaCl. The injections were performed submucosally during cystoscopy using a 3.7 Fr Williams cystoscopic injection needle (Cook Urological, Specer, IN, USA) into 20 injection sites. The procedure was performed using short intravenous anesthesia. In each case the bladder was filled with 200 ml of saline. After the procedure,
a Foley catheter was placed and then removed when the patient was discharged. Installing the catheter provided good drainage of urine in the postoperative period and enabled us to monitor the amount of bleeding. In the case of urinary retention or increase of the PVR over 200 ml, the patient was instructed to have a CIC (Photos 1, 2).

Urinalysis and urine culture were performed fourteen days after treatment and in this clinic visit PVR was re-evaluated by ultrasound examination. If

Figure 1. Flow diagram

Photo 1. Visible injection site by the colored drug solution

Photo 2. The drug solution spreads submucosal
PVR was more than 200 ml, the patients were recommended to have a CIC. The patients were re-assessed 6 and 12 weeks after the treatment using the Likert scale and OABSS questionnaire.

**Statistical analysis**

For comparison of baseline, after 6 and 12 weeks following the treatment score in the OABSS and Likert scale of the two treatment groups, continuous variables were analyzed by the Mann-Whitney-Wilcoxon test since groups and parameters were not normally distributed. Fisher’s exact test for count data was used to check the independence between the features described in the columns and rows of Table I. The assumed significance level is $\alpha = 0.05$. The results were generated using R statistics language [8].

**Results**

**Therapeutic effects**

The comparison between the study and the control group pertained to the total OABSS score, together with answers to specific questions 6 and 12 weeks following the treatment. There were no significant differences in total and symptom score at baseline and during follow-up (6 and 12 after treatment) between the two groups (Table II).

General improvement and reduction of specific symptoms were evaluated according to the Likert scale. Significant improvement was similar (result of 1 or 2 on the Likert scale) and was achieved in

**Table I. Likert scale**

| Are you satisfied with the botulinum toxin treatment of your condition? |
|-----------------------------------------------------------------------|
| 1 Very satisfied                                                      |
| 2 Satisfied                                                          |
| 3 Somewhat satisfied                                                  |
| 4 Neither dissatisfied nor satisfied                                  |
| 5 Somewhat dissatisfied                                               |
| 6 Dissatisfied                                                       |
| 7 Very dissatisfied                                                   |

**Table II. Comparison of the effectiveness of the treatment using the OABSS and Likert scale in the sixth and the twelfth week after treatment**

| Week | Scale     | BTX-A + MB average | BTX-A average | BTX-A + MB Median (min.–max.) | BTX-A Median (min.–max.) | P-value (Wilcoxon-Mann-Whitney test) |
|------|-----------|---------------------|---------------|-------------------------------|-------------------------|-------------------------------------|
| 0    | OABSS T   | 9.333               | 9.564         | 9 (5–15)                      | 9 (5–15)               | 0.772                               |
|      | OABSS D   | 1.556               | 1.615         | 2 (0–2)                       | 2 (0–2)                | 0.656                               |
|      | OABSS N   | 2.139               | 2.231         | 2 (0–3)                       | 2 (0–3)                | 0.635                               |
|      | OABSS U   | 4.028               | 4.026         | 4 (2–5)                       | 4 (3–5)                | 0.951                               |
|      | OABSS I   | 1.611               | 1.692         | 1.5 (0–5)                     | 2 (0–5)                | 0.890                               |
| 6    | OABSS T   | 4.222               | 4.205         | 2 (0–13)                      | 3 (0–13)               | 0.730                               |
|      | OABSS D   | 0.778               | 0.795         | 0.5 (0–3)                     | 1 (0–3)                | 0.826                               |
|      | OABSS N   | 1.167               | 1.179         | 1 (0–3)                       | 1 (0–3)                | 1.000                               |
|      | OABSS U   | 1.611               | 1.590         | 1 (0–5)                       | 1 (0–5)                | 0.995                               |
|      | OABSS I   | 0.667               | 0.641         | 0 (0–4)                       | 0 (0–4)                | 0.902                               |
|      | Likert    | 2.162               | 2.316         | 2 (1–7)                       | 2 (1–7)                | 0.830                               |
| 12   | OABSS T   | 4.389               | 4.462         | 3 (0–13)                      | 3 (0–13)               | 0.809                               |
|      | OABSS D   | 0.889               | 0.846         | 1 (0–3)                       | 1 (0–3)                | 0.996                               |
|      | OABSS N   | 0.972               | 1.051         | 1 (0–4)                       | 1 (0–4)                | 0.646                               |
|      | OABSS U   | 1.750               | 1.795         | 1 (0–5)                       | 1 (0–5)                | 0.882                               |
|      | OABSS I   | 0.778               | 0.770         | 0 (0–4)                       | 0 (0–4)                | 0.954                               |
|      | Likert    | 2.300               | 2.368         | 2 (1–6)                       | 2 (1–6)                | 0.846                               |

OABSS T – total score, OABSS D – daytime frequency score, OABSS N – nighttime frequency score, OABSS U – urgency score, OABSS I – urgency incontinence score.
66.7% and 69.2% after 6 weeks and in 63.9% and 64.1% after 12 weeks in the BTX-A + MB group and only-BTX-A group, respectively. Similarly, the Mann-Whitney-Wilcoxon test did not show a statistically significant difference between the groups at 6 and 12 weeks.

**Adverse effects**

Urinary tract infection developed in 1 (2.8%) and 7 (17.9%) patients receiving BTX-A + MB and only BTX-A, respectively. Urinary retention was observed in 1 (2.8%) and 3 (7.7%) patients receiving BTX-A + MB and only BTX-A, respectively. Considering the total number of patients with complications, 2 (5.6%) vs. 9 (23.1%), there was a significant difference between the two groups ($p = 0.049$) (Table III).

**Discussion**

Our results show that the combination of BTX-A and MB does not influence the effectiveness of the treatment. Based on major, multicentre studies conducted on large groups of patients, the therapeutic effect of BTX-A in the treatment of RIOAB is assessed at 60–65% [9–11]. We obtained similar results in our study (64.9% for the group with MB vs. 63.2% for the control group in week 12 – patients satisfied and very satisfied on the Likert scale). Similarly, the analysis of the OABSS questionnaire did not show a significant difference between the examined groups either in the overall score or the score of individual symptoms. However, our method may result in additional benefits. In order to exert its therapeutic activity, the toxin must disperse in the tissue. The addition of a color marker may be very helpful in controlling the proper administration of the drug and thus can both ease the procedure for the operator and, consequently, improve its effectiveness. The use of a colored solution allows for intraoperative control of the depth of injection, as well as easy identification of the parts that have not been covered. It may have an impact on less experienced operators. Our modified procedure could be performed more confidently by young urologists during training.

The most commonly observed adverse effects of using BTX-A in RIOAB treatment include urinary tract infection (UTI) and urine retention (UR). The UTI can result from any procedure with the use of an endoscope in the urinary tract – on average, it occurs in 8% (5–15%) of such cases. In the case of administering injections of BTX-A to the bladder, the mucosa is affected by tissue destruction, which increases the frequency of occurrence of UTI to 21.4% with the use of a standard dose of 100 IU of BTX-A [2]. Increased volume of retained urine is yet another factor that may lead to the development of UTI. We found significantly fewer complications (UTI and UR) in the test group 14 days after the procedure. This effect may be attributed to MB, whose bacteriostatic properties are well known [12] – in fact, the substance is successfully applied

**Table III.** Comparison of the total number of complications using Fisher’s exact test. There was significantly less UTI and UR in the group using MB

| RIOAB | Adverse events | $P$-value (Fisher’s exact test) |
|-------|----------------|-------------------------------|
|       | None | UTI + UR | Total |
| BTX-A + MB | N    | 34     | 2     | 36 |
|          | NR   | 94.4%  | 5.6%  | 100%  |
|          | NC   | 53.1%  | 18.2% | 48%  |
| BTX-A    | N    | 30     | 9     | 39 |
|          | NR   | 76.9%  | 23.1% | 100%  |
|          | NC   | 46.9%  | 81.8% | 52%  |
| Total    | N    | 64     | 11    | 75 |
|          | NR   | 85.3%  | 14.7% | 100%  |
|          | NC   | 100%   | 100%  | 100%  |

RIOAB – idiopathic refractory overactive bladder, BTX-A + MB – botulinum toxin + methylene blue, BTX-A – only botulinum toxin, UTI – urinary tract infection, UR – urinary retention, N – number of counts for the appropriate category, NR – percentage of the number of counts divided by the sum of numbers in the rows for the appropriate category, NC – percentage of the number of counts divided by the sum of numbers in the columns for the appropriate category.
Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial

in modern dressings for slow-healing wounds [13, 14]. The MB within the dressing physically binds with harmful bacterial byproducts (such as endotoxins), an action that may also increase patients’ benefit. As with all living cells, bacterial survival depends on tightly controlled redox stability that balances reductive and oxidative processes (conceptually similar to pH balances) in order to function and thrive. MB alters the redox environment and creates an environment unsustainable for bacterial survival [15, 16].

There are also reports indicating that MB may have neuroprotective properties. MB supports cellular respiration in mitochondria and strengthens synaptic connections, which is considered to lead to better cognitive abilities and memory. The MB acts as an additional electron medium, supporting cellular respiration in mitochondria, which leads to producing more energy available for cellular processes in the form of ATP [17–19]. The MB may be an attractive subject for further clinical trials in the case of various diseases within the range of overactive bladder, in which malfunction of nerve conduction is among possible etiological factors.

The weak point of our study is the small number of participants. The evaluation of the effectiveness of BTX-A therapy in our study was based on the analysis of questionnaires. It seems to be reasonable to repeat the test using an objective biomarker such as urinary nerve growth factor [20].

Conclusions

In our study, we did not prove the advantages of applying a therapy using MB for the effectiveness of treating RIOAB with BTX-A. Limited occurrence of UTI, which is one of the typical possible complications, seems to be an interesting effect which may be of interest in future trials. Perhaps the application of MB or another bacteriostatic substance/drug will allow for limiting the standard perioperative preventative antibiotic treatment. The pleiotropic property of MB seems interesting; however, further research conducted on a larger group of patients is required in order to evaluate the effectiveness of the method and devise a scheme for proper administration of MB.

Conflict of interest

The authors declare no conflict of interest.

References

1. Phe V, Wachter S de, Roupret M, et al. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn 2015; 34: 2-11.
2. Cox I, Cameron AP. Onabotulinumtoxin A for the treatment of overactive bladder. Res Rep Urol 2014; 6: 79-89.
3. Kovner E. Chapter 6: Practical aspects of administration of onabotulinumtoxin A. Neurourol Urodyn 2014; 33 Suppl 3: S327.
4. Khuri J, Samal V, Nemec D, et al. Intradetrusor versus suburothelial onabotulinumtoxin A injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 2012; 50: 904-7.
5. Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxin A for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2013; 30: 1242-8.
6. Manecksha RR, Cullen IM, Ahmad S, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxin A for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61: 928-35.
7. Szczypior M, Poltom W, Markuszewski M, et al. Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinumtoxin A. Scand J Urol 2017; 51: 474-8.
8. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018, Vienna, Austria. URL https://www.R-project.org/.
9. Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012; 63: 507-14.
10. Chapple C, Sievert KD, MacDiarmid S, et al. Onabotulinumtoxin A 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013; 64: 249-56.
11. Nitti VW, Dmochowski R, Herschorn S, et al. Onabotulinumtoxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189: 2186-93.
12. Dubos R. The relation of the bacteriostatic action of certain dyes to oxidation-reduction processes. J Exp Med 1929; 49: 575-92.
13. Coutts PM, Ryan J, Sibbald RG. Case series of lower-extremity chronic wounds managed with an antibacterial foam dressing bound with gentian violet and methylene blue. Adv Skin Wound Care 2014; 27 (3 Suppl 1): 9-13.
14. Edwards K. New twist on an old favorite: gentian violet and methylene blue antibacterial foams. Adv Wound Care (New Rochelle) 2016; 5: 11-8.
15. Hess CT. Clinical Guide to Skin and Wound Care. 6th edn. Lippincott Williams & Wilkins, Philadelphia, PA 2012.
16. Gardner S, Frantz R. Wound bioburden and infection. In: Wound Care Essentials: Practice Principles. 3rd edn. Baranoski S, Ayello EA (eds.). Lippincott Williams & Wilkins, Philadelphia, PA 2012; 126-56.
17. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012; 96: 32-45.
18. Poteet E, Winters A, Yan L, et al. Neuroprotective actions of methylene blue and its derivatives. PLoS One 2012; 7: e48279.
19. Gonzalez-Lima F, Barksdale BR, Rojas JC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol 2014; 88: 584-93.
20. Suh YS, Ko KI, Kim TH, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J 2017; 21: 270-81.

Received: 3.12.2018, accepted: 8.01.2019.